Impact of the Maraviroc-Resistant Mutation M434I in the C4 Region of HIV-1 gp120 on Sensitivity to Antibody-Mediated Neutralization

Access this Article

Search this Article

Author(s)

Abstract

We previously reported that a maraviroc (MVC)-resistant human immunodeficiency virus type 1variant, generated using in vitro selection, exhibited high sensitivity to several neutralizing monoclonal antibodies (NMAbs) and autologous plasma IgGs. The MVC-resistant variant acquired 4 sequential mutations in gp120: T297I, M434I, V200I, and K305R. In this study, we examined the mutation most responsible for conferring enhanced neutralization sensitivity of the MVC-resistant variant to several NMAbs and autologous plasma IgGs. The virus with the first resistant mutation, T297I, was sensitive to all NMAbs, whereas the passage control virus was not. The neutralization sensitivity of the variant greatly increased following its acquisition of the second mutation, M434I, in the C4 region. The M434I mutation conferred the greatest neutralizing sensitivity among the 4 MVC-resistant mutations. Additionally, the single M434I mutation was sufficient for the enhanced neutralization of the virus by NMAbs, autologous plasma IgGs, and heterologous sera relative to that of the parental virus.

Journal

  • Japanese Journal of Infectious Diseases

    Japanese Journal of Infectious Diseases 69(3), 236-243, 2016

    National Institute of Infectious Diseases, Japanese Journal of Infectious Diseases Editorial Committee

Codes

  • NII Article ID (NAID)
    130005151997
  • NII NACSIS-CAT ID (NCID)
    AA1132885X
  • Text Lang
    ENG
  • ISSN
    1344-6304
  • NDL Article ID
    027322395
  • NDL Call No.
    Z53-C450
  • Data Source
    NDL  J-STAGE 
Page Top